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Glycosaminoglycans are important for cell signaling and therefore for proper embryonic development and adult homeostasis.
Expressions of genes involved in proteoglycan/glycosaminoglycan (GAG) metabolism and of genes coding for growth factors
known to bind GAGs were analyzed during skin development by microarray analysis and real time quantitative PCR. GAG related
genes were organized in six categories based on their role in GAG homeostasis, viz. (1) production of precursor molecules, (2)
productionof core proteins, (3) synthesis of the linkage region, (4) polymerization, (5)modification, and (6) degradation of theGAG
chain. In all categories highly dynamic up- and downregulations were observed during skin development, including differential
expression of GAGmodifying isoenzymes, core proteins, and growth factors. In two mice models, one overexpressing heparanase
and one lacking C5 epimerase, differential expression of only few genes was observed. Data show that during skin development a
highly dynamic and complex expression of GAG-associated genes occurs. This likely reflects quantitative and qualitative changes
in GAGs/proteoglycans, including structural fine tuning, which may be correlated with growth factor handling.
1. Introduction
During various cell signaling processes, glycosaminoglycans
(GAGs), such as heparan sulfate (HS), chondroitin sulfate
(CS), and dermatan sulfate (DS), play a role in binding,
guiding, and modulating signaling molecules, e.g., growth
factors and morphogens [1–3]. In skin this role can be
illustrated by the importance ofGAGs in adult woundhealing
[2, 4] and in the extracellular matrix architecture formed
during dermal development [5, 6]. A further example to
illustrate the importance of GAGs comes from mice overex-
pressing heparanase, an enzyme involved in the degradation
of HS, showing accelerated hair growth [7], indicating its
involvement in hair follicle morphogenesis and homeostasis.
Other observations show that HS is involved in hair follicle
cycling, sebaceous gland morphogenesis, and homeostasis
[8]. Finally, HS and heparanase influence wound healing in
adult mice by enhancing keratinocyte migration and stimu-
lating blood vesselmaturation [9]. Taken together, GAGs play
an important role in skin healing and development and this
prompted us to evaluate the expression of GAG related genes
during (embryonic) development in skin.
Inhibition of the expression of genes coding for enzymes
involved in GAG modification reactions clearly indicates the
importance of GAGs during organogenesis [10], especially
with respect to growth factor handling. For example, mice
deficient in Ndst1 (N-deacetylase sulfotransferase isoenzyme
1) die neonatally due to several defects in which defective
sonic hedgehog (Shh) signaling is implicated [11, 12]; mice
deficient in Hs2st (heparan sulfate 2-O sulfotransferase)
or Glce (glucuronic acid epimerase) display renal agenesis
[13, 14], whereas mice deficient in Hs6st1 (heparan sulfate
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Figure 1: Experimental setup used for the analysis of gene expression involved in GAG biology during skin development in mice. Based on
literature data, specific time points in skin development were selected. RNA was isolated, verified, and subsequently analyzed with GeneChip
exon arrays and TLDA gene expression cards.
6-O sulfotransferase isozyme 1) show aberrant signaling of
VEGF (vascular endothelial growth factor) and impaired
lung development [15]. A skin phenotype of the above mouse
models, however, has not been reported.
In general, it is thought that specific modifications of
the GAG chain are involved in the binding and modulation
of signaling molecules resulting in cell-type and/or tissue
specific reactions [2, 3]. GAG mimetics like the RGTAs
(regenerating agents) have been used to treat skin disorders
and improve skin healing [16, 17]. To obtain insight in
GAG metabolism during skin development we studied the
expression of GAG related genes covering six functional
classes ranging from the synthesis of precursor molecules
to the synthesis and degradation of GAGs. In addition,
we probed the expression of a number of (GAG binding)
signaling molecules.
2. Materials and Methods
Anoverview of the experimental setup on the gene expression
during murine skin development is given in Figure 1.
2.1. Animals for the Study on Skin Development. NIH guide-
lines for the care and use of laboratory animals (NIH
publication 85–23 Rev. 1985) were followed. The study was
approved by the Ethics Committee of the Radboud university
medical center (DEC2005-111, project: 81027). C57BL6/jmice
were obtained from Elevage Janvier (Le Genest Saint Isle,
France). Mice aged 90 days (90 days post birth [P90]) were
used for timed mating and dorsal skin was collected at 14
days (E14) and 16 days after conception (E16). At E14 hair
follicle development is initiated, and at E16 this process is
almost completed in combination with a stratified epidermis
and organized dermis [18, 19]. For the RNA samples of E14,
dorsal skin of seven embryos from one female was pooled
and used for RNA isolation. Skin was isolated at E14 by snap
freezing the whole embryo in liquid nitrogen followed by
scraping the skin layer in a cryomicrotome with a scalpel to
minimize contamination with other embryonic tissues (skin
is very thin at this time point). Samples were stored at -80∘C.
RNA samples for E16 were taken from two females, collecting
dorsal skin form 7 embryos each. In addition, skin from 1-day
old pups (P1) and adult mice (P90)was collected. At P1 skin is
more organized and has been exposed to air [18, 19]. For the
two dorsal skin samples for P1, three pups from two females
were taken per sample. Two adult three-month old mice were
used for the two dorsal skin samples at P90. Samples for RNA
isolation for E16, P1, and P90 were collected by removing
dorsal skin and snap freezing it in liquid nitrogen and storage
at -80∘C.
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2.2. Tissue of Genetically Modified Mice. Skin samples of
glucuronic acid epimerase (Glce) knockout mice (E18.5 for
expression analysis; E17.5 and E18.5 for histological analysis)
and of heparanase overexpression (Hpse) mice (P70) were
provided by Prof. Dr. Jin-Ping Li (Department of Medical
Biochemistry and Microbiology, University of Uppsala, Swe-
den) and Prof. Dr. Israel Vlodavsky (Vascular and Cancer
Biology Research Center Rappaport Faculty of Medicine and
Research Institute Technion-Israel Institute of Technology,
Israel), respectively [7, 20]. For RNA isolation two wildtype
and two mutant mice were used of both mouse models.
2.3. RNA Isolation, Real Time Quantitative PCR, andMicroar-
ray Analysis. Frozen samples were grinded in a micro-
dismembrator (Sartorius, Bunnik, The Netherlands) and
RNA was isolated using the TRIZOL-method (Invitrogen,
Paisley, UK) in combination with RNeasy Mini kit with
DNAse step (Qiagen, Hilden, Germany). RNA quality was
assessed using the Bioanalyzer system (Agilent Technologies,
Amstelveen, The Netherlands). The RNA integrity numbers
(RIN, 27) were 8.8±0.25 (technical replicate N=2), 8.0±0.35,
8.5±0.55, and 7.3±0.2 for E14, E16, P1, and P90 (biological
replicates N=2), respectively. The same procedure was used
for the RNA isolation for the Glce knockout mouse and
Hpse overexpressionmouse.TheRINwas 6.5±0.51 forGlce-/-
samples and 8.0±0.48 forGlce+/+ and 6.3±0.3 and 7.7±0.6 for
HPA-TG and HPA-WT, respectively (all biological replicate
N=2).
Gene Chip Mouse exon 1.0 ST Arrays (Affymetrix, High
Mycombe, UK) were used to analyze gene expression for E14,
E16, P1, and P90 using 1 휇g of RNA per chip. Expression data
were preprocessed to check sensitivity and specificity of the
results based on Kadota et al. (2009) as shown in Uijtdewil-
ligen et al. (2016) [18, 21]. Gene level expression data were
calculated for the CORE transcripts (probe sets supported by
RefSeq mRNAs) using Affymetrix Expression Console soft-
ware with quantile normalization (all arrays are considered
to have an equal intensity distribution), GC-content back-
ground correction (probes with high GC-content hybridize
better, corrected forwith built-in probeswith different known
GC-contents) and summarization with the RMA algorithm
[22]. Data were imported into GeneSpring GX 7.3 (Agilent
Technologies), duplicates were averaged, and the expression
of each transcript was normalized to the median per array.
Real Time-Quantitative PCR (qPCR) was performed
using custom designed Taqman Low Density arrays (TLDA)
(Applied Biosystems, Nieuwerkerk aan de IJssel, the Nether-
lands) containing probes against genes involved in GAG
metabolism and GAG binding proteins (Supplementary data
Table 1). Glce and Hpse samples were analyzed using qPCR
using custom designed TLDA with an adapted design con-
taining additional GAG related genes (Supplementary data
Table 2).
For the TLDA cards, 100 ng cDNA in Taqman Universal
PCR Master Mix (Applied Biosystems) was loaded on the
TLDA card per slot and run on a 7900HTFast Real Time PCR
System (Applied Biosystems). Expression was analyzed based
on the threshold cycle (Ct) whichwas obtained using the SDS
2.3 software and RQManager 1.2 of Applied Biosystems using
the combined expression data of the tested TLDA cards. In
Microsoft Excel the reference genes for ΔCt calculation were
checked for stability of expression by analyzing the results of
the reference genes across all used TLDA cards and selecting
the reference genes with the smallest deviation across the
cards tested. Subsequently ΔCt values were calculated using
a reference gene with the smallest difference between the
average Ct found for the gene of interest and for the reference
gene. The obtained ΔCt values were further processed using
the 2−ΔΔCt method using P90 as a calibration point in case
of the developmental study and the wild type background
(C57BL6 mice) data in case of the two mouse models [23].
2.4. Statistical Methods. Statistical significance of the exon
array data was analyzed using ANOVA and Benjamini-
Hoghberg multiple testing correction [24]. Statistical signif-
icance of the TLDA card data was tested with an unpaired
T-test (2-tailed) using Microsoft Excel. Data with a statistical
threshold of p<0.10 and a fold threshold of >2.0 were
considered statistically significant.
3. Results
Genes involved in glycosaminoglycan (GAG) synthesis,mod-
ification, and degradation were studied during skin devel-
opment at 14 and 16 days after conception (E14 and E16,
respectively) and at one day after birth (P1) and compared
to mature skin of a 3 month old mouse (P90). In addition,
two mouse models, a Glce knockout mouse (E18.5) and an
Hpse overexpression mouse model (P70), were analyzed.
Taqman Low Density Array (TLDA) cards were designed to
contain genes involved in GAG metabolism (Supplementary
data Tables 1 and 2). The expression data obtained using
TLDA cards and exon arrays were screened for genes with 2-
fold differential expression at a statistical threshold of p<0.10
(Tables 1, 2, 3, and 4, Supplementary data Tables 4, 5, and 6).
In Tables 1–3 and Supplementary data Table 3, an
overview is given of the differentially expressed genes apply-
ing TLDA cards and exon arrays. In all categories of genes
involved in GAG metabolism, i.e., production of precursor
molecules, core proteins, synthesis of linkage region, poly-
merization, modification and degradation of the GAG chain,
and differences in expression were found (Tables 1–3). This
indicates a highly dynamic expression pattern during skin
development. Some isoenzymes were upregulated, whereas
other isoenzymes were downregulated, further stressing
metabolic complexity. This is, for instance, the case with
GFPT1 and 2, both rates limiting enzymes involved in the
production of hexosamines, and the isoenzymes HS 3-O
sulfotransferase 6 and 3b1.
With respect to the core proteins, differential expression
was found for both HS and CS/DS proteoglycans. Differential
expression was found for two of the four syndecans, viz. Sdc1
and Sdc4, three of the six glypicans, viz. Gpc2, Gpc3, and
Gpc6, andHspg2 (Tables 2 and 3).The syndecans were down-
regulated, while the glypicans were upregulated, indicating
an embryonic role for glypicans as described in literature
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Table 1: Comparison of the number of differentially expressed genes during skin development in mice (p<0.10, fold>2.0) based on real-time
qPCR and on exon array analysis.
Total genes System E14 vs. P90 E16 vs. P90 P1 vs. P90
Down Up Down Up Down Up
Production of precursors
43 TLDA 1 4 3 2 1 2
43 Exon 2 6 2 0 1 0
Overlap 0 2 2 0 1 0
Core proteins
14 TLDA 2 3 1 1 2 2
14 Exon 3 2 1 1 0 2
Overlap 2 2 0 1 0 2
Preparation of linkage region
8 TLDA 0 1 0 1 0 1
8 Exon 0 2 0 0 0 0
Overlap 0 0 0 0 0 0
Glycosaminoglycan chain polymerisation
13 TLDA 1 4 1 2 0 2
13 Exon 1 2 0 0 0 0
Overlap 0 0 0 0 0 0
Glycosaminoglycan chain modification
32 TLDA 1 9 0 5 0 8
32 Exon 1 3 0 3 0 1
Overlap 1 2 0 1 0 0
Glycosaminoglycan chain degradation
19 TLDA 2 2 3 1 0 1
19 Exon 3 1 1 1 2 0
Overlap 2 1 1 1 0 0
Growth factors
37 TLDA 0 13 3 8 1 11
37 Exon 2 14 3 10 1 4
Overlap 0 10 2 8 0 4
∗ P values for the exon array measurements were calculated using Benjamini–Hochberg multitesting correction. P values for the TLDA assay were calculated
using an unpaired T-test.
Overlap refers to genes differentially expressed in both TLDA card and exon array.
[25, 26].Hspg2, a secretedHS presenting proteoglycan coding
for perlecan [2], was found to be upregulated (Tables 2 and 3).
Based on the exon array the CS/DS core protein of versican
(Vcan) was upregulated at all time points (Supplementary
data Table 5).
The upregulated expression of genes involved in the
synthesis of the linkage region may signal increased GAG
synthesis during development since after the formation of the
linkage region the GAG chain is formed. For HS polymer-
ization differential expression was found for, e.g., Extl1 and
Extl2. Extl1 showed downregulation at E14 while Extl2 was
upregulated, and both enzymes are involved in the initiation
and elongation of the HS chain [2].
During and after synthesis of the glycosaminoglycan
chain, disaccharide units within the chain are specifically
modified. These modifications determine which effector
molecules can bind to the chain and thus play a role in cell
signaling [1, 3]. Upregulated expression was found for three
of the four N-deacetylase/N-sulfotransferases (Ndst; TLDA
cards, Table 2), especially isoenzyme Ndst3. Upregulation
was also found for two out of seven genes coding for 3-
O-sulfotransferases (Hs3st1 and Hs3st3b1), involved in 3-O
sulfation of GlcNS and GlnNAc residues, whereas one was
downregulated (Hs3st6).
The GlcNS and GlcNAc residues can also be 6-O sul-
fated by 6-O-sulfotransferases (Hs6st) [2] and selectively
desulfated extracellularly by two sulfatases (Sulf1 and Sulf2)
aided by two cofactors (Sumf1 and Sumf2) [2, 27]. Hs6st2
was upregulated at all time points (Table 3). Sulf1 was
upregulated during embryonic development, whereas Sumf2
was upregulated at E14 (Tables 2 and 3). These results
indicate that specific expression of GAG modifying enzymes
may play a role in specific cellular signaling during skin
development.
Within the class of genes encoding for GAG chain degra-
dation enzymes, two genes were differentially expressed.
Heparanase expression was downregulated at E14 and P1
(Tables 2 and 3), whereas N-sulfoglucosamine sulfohydrolase
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Table 2: Differentially expressed GAG related genes during skin development in mice in comparison to mature skin (p<0.10) based on
real-time qPCR.
E14 vs. P90 E16 vs. P90 P1 vs. P90
Gene symbol Full gene name and probe set P-value Relative change P-value Relative change P-value Relative change
Production of precursors
Galk1 ‡ Galactokinase 1 0.029 5.897 0.057 3.867 0.074 3.043
Mm00444182 m1
Galt ‡ Gal-1-P-Uridylyltransferase 0.042 0.573 0.027 0.497 0.832 0.964
Mm00489459 g1
Gfpt1 ‡ Glu-Fru-6-P-Transaminase 1 0.002 2.378 0.160 1.273 0.282 1.481
Mm00600127 m1
Gfpt2 ‡ Glu-Fru-6-P-Transaminase 2 0.269 0.772 0.079 0.494 0.356 0.780
Mm00496565 m1
Hk2 ‡ Hexokinase 2 0.027 0.652 0.253 1.390 0.586 0.904
Mm00443385 m1
Pgm3 ‡ Phosphoglucomutase 2 0.058 1.876 0.296 1.249 0.098 1.470
Mm00459270 m1
Pgm5 ‡ Phosphoglucomutase 5 0.002 4.053 0.033 2.792 0.019 2.515
Mm00723432 m1
Slc13a5 ‡ Solute Carrier Family 13 Member A5 Not detected Not detected Not detected
Mm00523288 m1
Slc26a9 ‡ Solute Carrier Family 26 Member A9 Not detected 0.036 0.264 0.023 0.318
Mm00628490 m1
Slc35a3 ‡ Solute Carrier Family 35 Member a3 0.008 0.444 0.060 0.567 0.455 0.811
Mm00523288 m1
Core proteins
Cd44 CD44 Molecule 0.018 0.536 0.171 0.637 0.223 1.385
Mm01277164 m1
Gpc2 ‡ Glypican 2 0.005 11.686 0.638 1.294 0.369 1.249
Mm00549650 m1
Gpc3 † Glypican 3 <0.001 6.765 0.019 3.734 0.013 8.044
Mm00516722 m1
Gpc6 ‡ Glypican 6 0.027 2.880 0.275 1.376 0.130 1.926
Mm00516235 m1
Hspg2 ‡ Perlecan 0.030 1.504 0.064 1.959 0.007 3.325
Mm01181179 g1
Sdc1 ‡ Syndecan 1 0.012 0.293 0.107 0.313 0.069 0.403
Mm00448918 m1
Sdc4 † Syndecan 4 0.002 0.201 0.039 0.240 0.065 0.471
Mm00488527 m1
Preparation of linkage region
B3gat1 훽-1,3-Glucuronyltransferase 1 Not detected Not detected Not detected
Mm00661499 m1
B3gat2 훽-1,3-Glucuronyltransferase 2 Not detected Not detected Not detected
Mm00549042 m1
B4galt2 ‡ 훽-1,4-Galactosyltransferase 2 0.023 4.562 0.059 2.679 0.038 3.384
Mm00479556 m1
Glycosaminoglycan chain polymerisation
Chpf ‡ Chondroitin Polymerizing Factor <0.001 2.991 0.059 1.865 0.050 2.401
Mm01262239 g1
Chsy1 ‡ CS Synthase 1 0.013 3.900 0.024 2.282 0.072 2.229
Mm01319178 m1
Chsy3 ‡ CS Synthase 3 0.026 4.006 0.075 2.184 0.101 2.013
Mm01545329 m1
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Table 2: Continued.
E14 vs. P90 E16 vs. P90 P1 vs. P90
Gene symbol Full gene name and probe set P-value Relative change P-value Relative change P-value Relative change
Csgalnact1 ‡ CS-GalNAc-transferase 1 0.099 0.496 0.098 0.475 0.634 1.128
Mm00555164 m1
Extl1 ‡ Exostoses (multiple)-like 1 Not detected Not detected Not detected
Mm00621977 s1
Extl2 ‡ Exostoses (multiple)-like 2 0.007 2.043 0.660 1.220 0.106 1.765
Mm00469621 m1
Has2 ‡ Hyaluronan Synthase 2 0.188 1.933 0.235 1.705 0.410 1.577
Mm00515089 m1
Glycosaminoglycan chain modification
Chst11 ‡ Chondroitin 4-O-Sulfotransferase 1 0.002 3.000 0.087 1.195 0.087 1.957
Mm00517563 m1
Chst14 ‡ Dermatan 4 Sulfotransferase 1 0.026 2.459 0.156 1.513 0.203 1.707
Mm00511291 s1
Chst2 ‡ Carbohydrate Sulfotransferase 2 0.014 3.664 0.010 3.145 0.006 2.773
Mm00490018 g1
Chst3 ‡ Chondroitin 6-O-Sulfotransferase 1 0.041 3.241 0.152 1.941 0.028 3.550
Mm00489736 m1
Chst8 ‡ GalNAc-4-O-Sulfotransferase 1 0.089 2.587 0.221 0.591 0.139 2.280
Mm00558321 m1
Hs3st1 ‡ HS 3-O-sulfotransferase 0.051 1.796 0.039 1.937 0.027 2.809
Mm01964038 m1
Hs3st3b1‡ HS 3-O-sulfotransferase 3b1 0.004 3.204 0.028 2.511 0.002 2.629
Mm00479621 m1
Hs3st6 ‡ HS 3-O-sulfotransferase 6 0.006 0.208 0.089 0.664 0.041 1.765
Mm01299930 m1
Hs6st2 HS 6-O-sulfotransferase 2 Not detected Not detected Not detected
Mm00479296 m1
Ndst1 ‡ N-deacet./N-sulfotrans. 1 0.118 1.487 0.140 1.449 0.054 2.202
Mm00447005 m1
Ndst2 ‡ N-deacet./N-sulfotrans. 2 0.008 1.347 0.001 2.017 0.002 2.021
Mm00447818 m1
Ndst3 ‡ N-deacet./N-sulfotrans. 3 0.004 4.708 0.041 7.910 0.004 12.034
Mm00453178 m1
Sulf1 ‡ Sulfatase 1 0.004 4.644 0.079 2.674 0.089 2.077
Mm00552283 m1
Sumf2 ‡ Sulfatase modifying factor 2 0.008 2.657 0.104 2.023 0.038 1.857
Mm01197721 m1
Glycosaminoglycan chain degradation
ArsJ ‡ Arylsulfatase J 0.013 7.805 0.010 12.075 0.014 7.146
Mm00557970 m1
ArsK ‡ Arylsulfatase K 0.306 0.801 0.059 0.466 0.143 0.678
Mm00513099 m1
Galns ‡ Galactosamine (N-Acetyl)-6-Sulfatase <0.001 2.648 0.066 1.674 0.091 1.584
Mm00489575 m1
Hpse ‡ Heparanase 0.044 0.304 0.342 1.450 0.169 0.578
Mm00461768 m1
Hyal1 ‡ Hyaluronoglucosamini-dase 1 0.001 0.198 0.008 0.288 0.006 0.607
Mm00476206 m1
Sgsh ‡ N-Sulfoglucosamine Sulfohydrolase 0.055 0.647 0.002 0.435 0.644 0.897
Mm00450747 m1
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Table 2: Continued.
E14 vs. P90 E16 vs. P90 P1 vs. P90
Gene symbol Full gene name and probe set P-value Relative change P-value Relative change P-value Relative change
Growth factors
Areg Amphiregulin Not detected Not detected 0.656 0.834
Mm00437583 m1
Bmp3 ‡ Bone morphogenetic growth factor 3 0.007 4.270 0.004 7.240 0.002 11.628
Mm00557790 m1
Bmp5 ‡ Bone morphogenetic growth factor 5 0.022 12.051 0.303 1.788 0.587 1.300
Mm00432091 m1
Ctgf ‡ Connective tissue growth factor 0.668 1.079 0.011 0.232 0.076 0.580
Mm01192931 g1
Fgf10 ‡ Fibroblast growth factor 10 0.063 1.649 0.050 1.801 0.093 2.262
Mm00433275 m1
Fgf13 ‡ Fibroblast growth factor 13 0.002 3.205 0.059 1.750 0.181 1.544
Mm00438910 m1
Fgf2 ‡ Fibroblast growth factor 2 0.277 0.651 0.166 0.539 0.382 1.446
Mm01285715 m1
Fgf20 Fibroblast growth factor 20 Not detected Not detected Not detected
Mm00748347 m1
Fgf22 ‡ Fibroblast growth factor 22 Not detected 0.386 0.632 0.060 0.614
Mm00445749 m1
Fgf7 ‡ Fibroblast growth factor 7 0.045 0.606 0.002 0.394 0.087 0.630
Mm00433291 m1
Fgf8 Fibroblast growth factor 8 Not detected Not detected Not detected
Mm00438921 m1
Figf ‡ C-fos induced growth factor 0.081 1.397 0.030 1.787 0.545 0.834
Mm01131929 m1
Gdf10 ‡ Growth differentaition factor 10 0.015 3.181 0.454 1.143 0.166 1.519
Mm03024279 s1
Hbegf ‡ Heparin-binding epidermal growth factor Not detected 0.015 0.347 0.016 0.423
Mm00439305 g1
Hdgf † Hepatoma-derived growth factor 0.257 1.221 0.737 0.911 0.975 1.008
Mm00725733 s1
Igf1 ‡ Insulin-like growth factor 1 0.320 1.207 0.217 0.705 0.364 0.790
Mm00439560 m1
Igf2 † Insulin-like growth factor 2 <0.001 592.335 0.002 338.094 0.001 416.096
Mm00439565 g1
Nog ‡ Noggin 0.054 2.945 0.019 2.935 0.021 3.067
Mm01297833 s1
Pdgfa ‡ Platelet-derived growth factor a 0.021 3.005 Not detected 0.016 3.669
Mm01205760 m1
Pdgfb ‡ Platelet-derived growth factor b 0.321 1.098 0.033 1.468 0.010 2.096
Mm01298578 m1
Pdgfc ‡ Platelet-derived growth factor c Not detected 0.016 2.362 Not detected
Mm00480205 m1
Pdgfd ‡ Platelet-derived growth factor d Not detected 0.288 0.709 0.139 1.644
Mm00546829 m1
Shh Sonic hedgehog Not detected Not detected Not detected
Mm00436527 m1
Tgfb1 ‡ Transforming growth factor beta 1 0.027 0.540 0.488 0.817 0.157 1.372
Mm01178820 m1
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Table 2: Continued.
E14 vs. P90 E16 vs. P90 P1 vs. P90
Gene symbol Full gene name and probe set P-value Relative change P-value Relative change P-value Relative change
Tgfb2 ‡ Transforming growth factor beta 2 0.039 2.697 0.757 1.081 0.127 1.809
Mm01321739 m1
Tgfb3 ‡ Transforming growth factor beta 3 0.033 2.420 0.094 1.854 0.034 2.517
Mm01307950 m1
Vegfa ‡ Vascular endothelial growth factor a 0.394 1.108 0.112 1.613 0.461 1.358
Mm01281447 m1
Vegfb Vascular endothelial growth factor b Not detected Not detected Not detected
Mm00442102 m1
Vegfc ‡ Vascular endothelial growth factor c 0.024 1.839 0.303 1.250 0.015 1.996
Mm00437313 m1
Wnt10b ‡ Wingless-related integration site 10b 0.180 5.829 0.122 9.688 0.105 11.748
Mm00442104 m1
Wnt16 ‡ Wingless-related integration site 16 0.066 2.094 0.016 4.809 0.014 4.362
Mm00446420 m1
Wnt2 ‡ Wingless-related integration site 2 0.054 3.144 0.090 3.555 0.074 3.760
Mm00470018 m1
Wnt2b Wingless-related integration site 2b Not detected Not detected Not detected
Mm00437330 m1
Wnt3a ‡ Wingless-related integration site 3a 0.394 1.610 0.441 1.520 0.840 1.106
Mm00437337 m1
Wnt6 ‡ Wingless-related integration site 6 0.015 11.709 0.018 10.400 0.016 10.758
Mm00437353 m1
Wnt7a Wingless-related integration site 7a Not detected Not detected Not detected
Mm00437355 m1
Wnt7b ‡ Wingless-related integration site 7b 0.003 4.180 0.056 6.076 0.003 4.181
Mm00437357 m1
Numbers in italic are significant (p<0.10); numbers in bold are >2-fold differentially expressed. Gene symbols indicated with a †-symbol are normalized using
GAPDH as a reference gene. Gene symbols indicated with a ‡-symbol are normalized using TBP as a reference gene. Genes, for which a signal was not or only
partly detected at a given time point or multiple time points and therefore a fold change and/or p value could not be calculated based on the available data, are
given as “not detected.” Gene symbols for which all time points were classified as “not detected” do not show a symbol for the used reference gene due to lack
of data for a calculation.
(Sgsh) was downregulated during embryonic development at
E16 (Table 2) and at E14 (Table 3).
In addition to genes involved in GAG metabolism, the
TLDA card contained 37 genes encoding growth factors,
which were also present in the microarray (Tables 2 and 3).
Differential expression was found by both TLDA card and
microarray analysis for 10, 9 and 4 growth factors at E14,
E16 and P1 respectively. Examples are insulin-like growth
factor 2 (Igf2), wingless-related integration site 6 (Wnt6), and
Wnt7b. Igf2 was dramatically upregulated at all time points,
as expected based on previous research [18]. Wnt6 was also
upregulated at all time points, while Wnt7b was upregulated
only during embryonic development.
Next to their expression during development, gene
expression of GAG-associated genes was studied in a
Glce (glucuronyl epimerase) knockout mouse model and
a heparanase overexpression mouse model using TLDA
cards. In the Glce knockout mice six genes were differ-
entially expressed (Table 4). Three of them are involved
in CS and DS proteoglycans and were downregulated,
i.e., aggrecan (Acan), asporin (Aspn), and chondroitin
sulfate N-acetylgalactosaminyltransferase 2 (Csgalnact2).
Up/downregulation was not found for HS related genes,
except for Glce, which was downregulated as expected. For
the heparanase overexpression mouse model, in which a
human heparanase was overexpressed [7], the results showed
only one gene to be differentially expressed, i.e., aggrecan
(Acan) which was 2.5-fold upregulated. The complete results
of both the Glce knockout mouse and the Hpse overexpres-
sion mouse are given in Supplementary data Table 6.
4. Discussion
GAGs play a regulating role during embryonic develop-
ment of various organs [1–3]. Therefore, we examined the
expression of genes involved in GAGmetabolism during skin
development using custom designed Taqman Low Density
Arrays (TLDA card) and exon arrays. To structure the
data we studied gene expression in six functional classes,
viz. the production of precursor molecules, the synthesis
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Table 3: Differentially expressed GAG related genes during skin development in mice in comparison to mature skin (p<0.10) based on gene
Chip Mouse Exon 1.0 ST Arrays.
E14 vs. P90 E16 vs. P90 P1 vs. P90
Gene
symbol Full gene name and probe set Stepup P-value Fold change
Stepup
P-value
Fold
change
Stepup
P-value
Fold
change
Production of precursors
Galk1 Galactokinase 1 0.030 4.242 0.126 2.483 0.231 2.194
6792485
Galt Gal-1-P-Uridylyltransferase 0.664 0.814 0.231 1.864 0.665 1.340
6912944
Gfpt1 Glu-Fru-6-P-Transaminase 1 0.020 2.110 0.077 1.682 0.801 1.081
6947679
Gfpt2 Glu-Fru-6-P-Transaminase 2 0.176 0.610 0.087 0.426 0.229 0.547
6780767
Hk2 Hexokinase 2 0.003 0.451 0.040 1.375 0.039 0.655
6954982
Pgm3 Phosphoglucomutase 2 0.083 2.193 0.676 1.178 0.654 1.286
6997513
Pgm5 Phosphoglucomutase 5 0.058 2.338 0.104 2.209 0.291 1.696
6872290
Slc13a5 Solute Carrier Family 13 Member A5 0.003 2.588 0.059 1.322 0.576 1.075
6789531
Slc26a9 Solute Carrier Family 26 Member A9 0.012 0.227 0.090 0.471 0.091 0.392
6753079
Slc35a3 Solute Carrier Family 35 Member A3 0.105 0.767 0.596 0.925 0.572 0.890
6908510
Core proteins
Cd44 CD44 Molecule 0.009 0.370 0.144 0.728 0.873 0.955
6889258
Gpc2 Glypican 2 Not measured Not measured Not measured
Gpc3 Glypican 3 0.003 4.339 0.013 3.305 0.015 4.721
7016826
Gpc6 Glypican 6 0.019 2.767 0.109 1.747 0.193 1.640
6821985
Hspg2 Perlecan 0.309 1.183 0.075 1.554 0.042 2.230
6917933
Sdc1 Syndecan 1 0.031 0.380 0.067 0.413 0.103 0.424
6793226
Sdc4 Syndecan 4 0.017 0.341 0.094 0.536 0.215 0.621
6892905
Preparation of linkage region
B3gat1 훽-1,3-Glucuronyltransferase 1 0.008 3.467 0.256 1.302 0.828 0.929
6987632
B3gat2 훽-1,3-Glucuronyltransferase 2 0.009 3.241 0.286 1.269 0.690 1.129
6748174
B4galt2 훽-1,4-Galactosyltransferase 2 0.039 1.726 0.053 1.856 0.176 1.477
6924869
Glycosaminoglycan chain polymerisation
Chpf Chondroitin Polymerizing Factor 0.071 1.679 0.182 1.459 0.309 1.403
6759816
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Table 3: Continued.
E14 vs. P90 E16 vs. P90 P1 vs. P90
Gene
symbol Full gene name and probe set Stepup P-value Fold change
Stepup
P-value
Fold
change
Stepup
P-value
Fold
change
Chsy1 CS Synthase 1 Not measured Not measured Not measured
Chsy3 CS Synthase 3 0.429 1.153 0.056 1.769 0.849 1.058
6861281
Cs-
galnact1 CS-GalNAc-transferase 1 0.137 0.512 0.202 0.541 0.974 0.975
6983073
Extl1 Exostoses (multiple)-like 1 0.025 0.407 0.149 0.625 0.144 0.505
6926017
Extl2 Exostoses (multiple)-like 2 0.085 1.702 0.819 1.066 0.518 1.272
6900659
Has2 Hyaluronan Synthase 2 0.095 2.107 0.157 1.969 0.537 1.403
6854042
Glycosaminoglycan chain modification
Chst11 Chondroitin 4-O-Sulfotransferase 1 0.049 1.922 0.465 1.208 0.239 1.531
6769366
Chst14 Dermatan 4 Sulfotransferase 1 0.151 1.491 0.506 1.191 0.773 1.122
6880476
Chst2 Carbohydrate Sulfotransferase 2 0.035 2.302 0.072 2.160 0.207 1.682
6997990
Chst3 Chondroitin 6-O-Sulfotransferase 1 0.885 1.034 0.108 1.545 0.162 1.530
6774295
Chst8 GalNAc-4-O-Sulfotransferase 1 0.945 1.007 0.569 1.054 0.420 1.108
6966453
Hs3st1 HS 3-O-sulfotransferase 1 0.074 1.658 0.105 1.688 0.119 1.824
6937654
Hs3st3b1 HS 3-O-sulfotransferase 3b1 0.683 1.178 0.253 1.634 0.511 1.432
6788991
Hs3st6 HS 3-O-sulfotransferase 6 0.019 0.406 0.291 0.771 0.721 1.130
6849317
Hs6st2 HS 6O-sulfotransferase 2 0.004 6.417 0.012 5.609 0.041 3.080
7016808
Ndst1 N-Deacetylase and N-Sulfotransferase 1 0.090 1.363 0.056 1.649 0.067 1.763
6865926
Ndst2 N-Deacetylase and N-Sulfotransferase 2 0.822 1.044 0.059 1.697 0.083 1.733
6823122
Ndst3 N-Deacetylase and N-Sulfotransferase 3 0.173 2.472 0.111 3.856 0.122 4.860
6908958
Sulf1 Sulfatase 1 0.010 4.522 0.051 2.546 0.232 1.627
6747641
Sumf2 Sulfatase modifying factor 2 Not measured Not measured Not measured
Glycosaminoglycan chain degradation
ArsJ Arylsulfatase J 0.003 2.498 0.006 3.164 0.031 1.702
6901136
ArsK Arylsulfatase K 0.368 0.784 0.102 0.543 0.514 0.779
6814451
Galns Galactosamine (N-Acetyl)-6-Sulfatase 0.087 1.671 0.322 1.311 0.786 1.115
6985943
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E14 vs. P90 E16 vs. P90 P1 vs. P90
Gene
symbol Full gene name and probe set Stepup P-value Fold change
Stepup
P-value
Fold
change
Stepup
P-value
Fold
change
Hpse Heparanase 0.021 0.267 0.540 1.244 0.095 0.360
6940363
Hyal1 Hyaluronoglucosamini-dase 1 0.003 0.154 0.011 0.222 0.041 0.402
6992224
Sgsh N-Sulfoglucosamine Sulfohydrolase 0.017 0.458 0.052 0.537 0.201 0.699
6792702
Growth factors
Areg Amphiregulin 0.016 0.157 0.043 0.200 0.333 0.550
6932394
Bmp3 Bone morphogenetic growth factor 3 0.280 1.392 0.067 2.381 0.100 2.365
6932718
Bmp5 Bone Morphogenetic growth factor 5 0.001 7.247 0.141 1.191 0.688 1.057
6990569
Ctgf Connective tissue growth factor 0.148 0.729 0.025 0.366 0.068 0.485
6766623
Fgf10 Fibroblast growth factor 10 0.138 1.521 0.057 2.250 0.094 2.142
6810592
Fgf13 Fibroblast growth factor 13 0.012 2.998 0.075 1.824 0.296 1.391
7017134
Fgf2 Fibroblast growth factor 2 0.201 0.664 0.279 0.696 0.952 0.967
6896850
Fgf20 Fibroblast growth factor 20 0.659 1.228 0.125 2.483 0.777 1.220
6981854
Fgf22 Fibroblast growth factor 22 0.005 0.329 0.972 0.994 0.097 0.646
6769141
Fgf7 Fibroblast growth factor 7 0.531 0.740 0.078 0.286 0.212 0.418
6880900
Fgf8 Fibroblast growth factor 8 0.492 0.883 0.655 1.085 0.682 0.895
6873363
Figf C-fos induced growth factor 0.051 1.734 0.062 1.909 0.548 0.832
7015007
Gdf10 Growth differentiation factor 10 0.028 2.334 0.757 1.086 0.894 1.060
6818153
Hbegf Heparin-binding epidermal growth factor 0.037 0.551 0.063 0.547 0.087 0.530
6864680
Hdgf Hepatoma-derived growth factor 0.104 1.246 0.575 1.070 0.409 1.147
6899028
Igf1 Insulin-like growth factor 1 0.235 0.631 0.173 0.537 0.398 0.641
6769597
Igf2 Insulin-like growth factor 2 0.001 59.615 0.002 55.864 0.002 52.364
6972317
Nog Noggin 0.275 2.605 0.517 1.773 0.677 1.712
6790670
Pdgfa Platelet-derived growth factor a 0.028 2.013 0.035 2.347 0.057 2.338
6942654
Pdgfb Platelet-derived growth factor b 0.037 0.704 0.199 1.197 0.157 1.298
6837144
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Table 3: Continued.
E14 vs. P90 E16 vs. P90 P1 vs. P90
Gene
symbol Full gene name and probe set Stepup P-value Fold change
Stepup
P-value
Fold
change
Stepup
P-value
Fold
change
Pdgfc Platelet-derived growth factor c 0.019 2.152 0.035 2.207 0.902 1.042
6898686
Pdgfd Platelet-derived growth factor d 0.925 0.952 0.191 0.504 0.790 1.205
6986677
Shh Sonic hedgehog 0.448 0.595 0.308 2.117 0.152 4.571
6936889
Tgfb1 Transforming growht factor beta 1 0.106 0.552 0.241 0.653 0.975 0.981
6959236
Tgfb2 Transforming growht factor beta 2 0.057 2.441 0.448 1.335 0.264 1.802
6764953
Tgfb3 Transforming growth factor beta 3 0.026 2.386 0.238 1.408 0.100 2.077
6802449
Vegfa Vascular endothelial growth factor a 0.779 0.875 0.721 1.174 0.940 1.061
6855659
Vegfb Vascular endothelial growth factor b 0.008 1.461 0.031 1.318 0.060 1.277
6871273
Vegfc Vascular endothelial growth factor c 0.088 2.120 0.477 1.316 0.316 1.700
6976200
Wnt10b Wingless-related integration site 10b 0.629 1.280 0.120 2.812 0.240 2.325
6838399
Wnt16 Wingless-related integration site 16 0.358 1.180 0.026 2.402 0.093 1.710
6944581
Wnt2 Wingless-related integration site 2 0.057 3.047 0.082 3.260 0.122 3.219
6951974
Wnt2b Wingless-related integration site 2b 0.009 2.189 0.024 2.030 0.077 1.590
6907887
Wnt3a Wingless-related integration site 3a 0.457 1.199 0.103 1.728 0.684 1.159
6788662
Wnt6 Wingless-related integration site 6 0.011 3.166 0.032 2.668 0.064 2.352
6750567
Wnt7a Wingless-related integration site 7a 0.060 2.117 0.131 1.865 0.395 1.456
6955539
Wnt7b Wingless-related integration site 7b 0.072 2.297 0.050 3.623 0.237 1.912
6837582
Numbers in Italic are significant (p<0.10); numbers in bold are >2-fold differentially expressed. Genes indicated as “not measured” represent genes for which
probes were not available on the used exon array version.
of core proteins and the linkage region, and the synthesis,
modification, and degradation of the GAG chain proper.
In addition we studied a number of growth factors, since
GAGs are involved in their regulation including growth factor
diffusion and signaling [3, 28].
With respect to core proteins, the heparan sulfate proteo-
glycans syndecan and glypican showed notable differential
expression (Tables 2 and 3). Glypicans play an important
role in development and cell signaling [12, 26, 29], and we
found upregulation of 3 out of 6 glypican core proteins.
Gpc3 was upregulated during embryonic development and
one day postbirth, suggesting that this glypican has a role
during skin development. A possible function ofGpc3 in skin
has been suggested for the Gpc3-null mouse, which showed
pigmentation defects [30]. Humans deficient in Gpc3 suffer
from the Simpson-Golabi-Behmel syndrome (SBGS). Based
on the symptoms of SGBS and the phenotype found for the
Gpc3-null mice, it has been suggested that Gpc3 is involved in
the regulation of hedgehog signaling [31], a signaling pathway
involved in hair follicle development [32]. Surprisingly, the
Gpc3-null mice did not show a defect in appendage formation
[30], indicating a functional but not essential role. Further
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Table 4: Differentially expressed genes in C5 epimerase (Glce) knockout mouse (p<0.10) based on real-time qPCR.
Gene symbol Full gene name and probe set P-value Relative change
Production of precursors
Gnpnat1 Glucosamine-Phosphate N-Acetyltransferase 1 0.033 0.468
Mm00834602 mH
Slc2a4 Solute Carrier Family 2 Member 4 0.086 2.526
Mm01245507 g1
Core proteins
Acan Aggrecan 0.005 0.242
Mm00545807 m1
Aspn Asporin 0.010 0.382
Mm00445945 m1
Glycosaminoglycan chain polymerisation
Csgalnact CS N-Acetylgalactosaminyltransferase 2 0.049 0.431
2 Mm00513340 m1
Glycosaminoglycan chain modification
Glce Glucuronic Acid Epimerase 0.013 0.079
Mm00473667 m1
Numbers in Italic are significant (p<0.10); numbers in bold are >2 fold differentially expressed.
All genes were normalized using 18S RNA as a reference gene.
research is needed to elucidate the role of Gpc3 and the two
other differentially expressed glypicans, i.e., Gpc2 and Gpc6.
Syndecans are described to take part in adult wound
healing [33].We found downregulation of the core proteins of
two syndecans during embryonic development, which could
indicate that these proteoglycans do not play a major general
role during skin development. Specific roles, such as the
involvement of Sdc1 in hair follicle development, as described
on basis of immunohistochemical data [34], can, however,
not be excluded.
In the class of GAG chain polymerization, we found
differential expression of genes encoding for the initiation
of HS or CS/DS synthesis. HS chain polymerization is
initiated by the addition of GlcNAc by Extl2 [35] or Extl3
[36], while CS/DS chain polymerization is initiated by the
addition of GalNAc byCsgalnact1 [37]. Extl2 was upregulated
during early skin development (Table 2), while Csgalnact1
was downregulated (Supplementary data Table 5), which
suggests that during early skin development HS production
is stimulated in comparison to CS/DS production.
Enzyme mediated chemical modifications of the GAG
chains result in the creation of specific binding sites for
effector molecules [38]. Enzymes forming the class of N-
deacetylase/sulfotransferases (Ndst’s) are initiating elements
in this respect. Especially Ndst3 was upregulated, being
one of four enzymes responsible for the removal of the
acetyl group from the N-acetylated glycosamine and for the
addition of a sulfate group. The additional expression of
Ndst3 in combination with Ndst1 and Ndst2 points to the
fine tuning of HS chains for specific recognition of ligands.
Ndst3 has a higher deacetylation activity in comparison
to the N-sulfotransferase activity, while Ndst1 and Ndst2
have a slightly higher N-sulfotransferase activity [39]. In
addition, the data on the expression of heparan sulfate
3-O sulfotransferases (Hs3sts) [40] and heparan sulfate
6-O-sulfotransferases (Hs6sts) [41] suggest dynamic and
specific modification of HS chains.
Three genes encoding for enzymes involved in HS and
CS/DS degradation were differentially expressed, one of
them being Hpse (heparanase). Hpse is downregulated at E14
and at P1, but not at E16 at which time point hair follicle
development is taking place. Hpse has been reported to be
involved in this process [42, 43].
Glycosaminoglycans are involved in growth factor reg-
ulation during developmental processes [1, 2]. We therefore
studied 37 growth factors implied in skin development. A
number of genes encoding growth factors were differentially
expressed during development and the data are in line with
earlier results for, e.g., Igf2 [18], Wnt6, and Wnt7b [44].
Although speculative, the dynamics in GAG structure may
be correlated with the dynamics of growth factors.
Next to skin developmentwe also studied gene expression
in skin of aGlce (glucuronyl epimerase) knockout mouse and
an Hpse (heparanase) overexpression mouse [7, 13]. In the
Glce knockout mice relatively few genes were differentially
expressed, suggesting that skin is relatively unaffected by the
lack ofGlce in linewith the observation that skin in thesemice
is phenotypically normal [20]. The skin phenotype of the
Hpse overexpression mouse shows accelerated hair growth
[7]. Gene expression analysis of this model showed only one
differentially expressed gene (aggrecan). These results may
touchupon the regulation of translation ofmRNAs coding for
GAG related enzymes. Enzymes involved in the synthesis and
modification of GAGs as well genes coding for (some) growth
factors share a common alternative translation mechanism
via IRES sites [45, 46]. In general mRNAs are translated by
the ribosomal scanning mechanism which scans for short
leader sequences of 50 to 70 nucleotides [46, 47]. The leader
sequences of the HS modifying enzymes and growth factors
are characterized by long but structured sequences, which
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are not recognized by the ribosomal scanning mechanism
[46, 47]. Within these sequences internal ribosomal entry
sites (IRES) allow alternative translation, e.g., under stress
conditions [47]. This indicates that in addition to mRNA
levels an additional control mechanism on the translational
level may be present. In addition, other types of regulatory
levels are known including the interaction of biosynthetic
enzymes with each other and the (possible) presence of
large biosynthetic complexes (GAGosomes) [48].This makes
the regulation of GAG biosynthesis very complex, gene
expression being only a part of it.
Taken together, it is concluded that a highly dynamic
expression of genes involved in GAG metabolism and in
GAG binding growth factors is associated with skin develop-
ment. This indicates the importance of fine tuning of GAG
structures during developmental processes. Further studies
should focus on the biochemical analysis of the GAGs chains
themselves.
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